menu
    • menu
    [{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-hydroxytryptamine receptor 6; Sigma non-opioid intracellular receptor 1; 5-hydroxytryptamine receptor 2A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centre for Human Drug Research \/ Centre for Human Drug Research","highestDevelopmentStatusID":"6","companyTruncated":"Centre for Human Drug Research \/ Centre for Human Drug Research"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Recordati Rare Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Centre for Human Drug Research \/ Recordati Rare Diseases","highestDevelopmentStatusID":"1","companyTruncated":"Centre for Human Drug Research \/ Recordati Rare Diseases"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Human Drug Research \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Centre for Human Drug Research \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"QurAlis","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"QRL-101","moa":"Kv7.2\/Kv7.3","graph1":"Undisclosed","graph2":"Phase I","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Human Drug Research \/ Centre for Human Drug Research","highestDevelopmentStatusID":"6","companyTruncated":"Centre for Human Drug Research \/ Centre for Human Drug Research"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centre for Human Drug Research \/ Aim ImmunoTech","highestDevelopmentStatusID":"4","companyTruncated":"Centre for Human Drug Research \/ Aim ImmunoTech"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Axoltis","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"NX210c","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Human Drug Research \/ Centre for Human Drug Research","highestDevelopmentStatusID":"6","companyTruncated":"Centre for Human Drug Research \/ Centre for Human Drug Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Centre for Human Drug Research

    Menu

    Centre for Human Drug Research

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QRL-101

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : QurAlis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability...

                            Details : QRL-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 08, 2024

                            Lead Product(s) : QRL-101

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : QurAlis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX210c

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Axoltis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MAD Study of NX210c

                            Details : NX210c is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 25, 2023

                            Lead Product(s) : NX210c

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Axoltis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Recipient : Algernon Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single and Repeat Doses of DMT in Healthy Subjects

                            Details : N,N-Dimethyltryptamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Stroke.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 29, 2022

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Recipient : Algernon Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Recordati Rare Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides

                            Details : Chlormethine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Mycosis Fungoides.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Recordati Rare Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Aim ImmunoTech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen

                            Details : CHDR, will conduct and manage the proposed clinical study, titled “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subject...

                            Product Name : Ampligen

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 29, 2021

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Aim ImmunoTech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed

                            Centre for Human Drug Research

                            Netherlands arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Guselkumab

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Explorative Psoriasis Biomarker Study

                            Details : Guselkumab is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Psoriasis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 20, 2020

                            Lead Product(s) : Guselkumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth